Literature DB >> 2590204

Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues.

M Ulvsbäck1, C Lindström, H Weiber, P A Abrahamsson, H Lilja, A Lundwall.   

Abstract

In order to study the gene expression of the seminal plasma protein beta-microseminoprotein, also known as PSP94 and beta-inhibin, clones encoding this protein were isolated from a cDNA library constructed in lambda gt11. Nucleotide sequencing confirmed the structure of a previously cloned cDNA. By northern blot analysis identical sized transcripts were demonstrated in the prostate, the respiratory (tracheal, bronchial and lung) tissues and the antrum part of the gastric mucosa. Thus, the protein is not primarily associated with male reproductive function. Although probably of no physiological significance, a slight structural similarity to the ovarian inhibin beta-chains was identified in the C-terminal half of the molecule.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590204     DOI: 10.1016/0006-291x(89)91812-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  beta-Microseminoprotein binds CRISP-3 in human seminal plasma.

Authors:  Lene Udby; Ake Lundwall; Anders H Johnsen; Per Fernlund; Camilla Valtonen-André; Anna M Blom; Hans Lilja; Niels Borregaard; Lars Kjeldsen; Anders Bjartell
Journal:  Biochem Biophys Res Commun       Date:  2005-07-29       Impact factor: 3.575

2.  A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations.

Authors:  Kevin M Waters; Daniel O Stram; Loic Le Marchand; Robert J Klein; Camilla Valtonen-André; Mari T Peltola; Laurence N Kolonel; Brian E Henderson; Hans Lilja; Christopher A Haiman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-24       Impact factor: 4.254

3.  Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease.

Authors:  Benjamin L Nicholas; Paul Skipp; Sheila Barton; Dave Singh; Dinesh Bagmane; Richard Mould; Gilbert Angco; Jon Ward; Binita Guha-Niyogi; Susan Wilson; Peter Howarth; Donna E Davies; Stephen Rennard; C David O'Connor; Ratko Djukanovic
Journal:  Am J Respir Crit Care Med       Date:  2010-01-28       Impact factor: 21.405

4.  Beta microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions.

Authors:  H Weiber; C Andersson; A Murne; G Rannevik; C Lindström; H Lilja; P Fernlund
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

5.  Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.

Authors:  Xing Xu; Camilla Valtonen-André; Charlotta Sävblom; Christer Halldén; Hans Lilja; Robert J Klein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08       Impact factor: 4.254

6.  Characterization of ostrich (Struthio camelus) beta-microseminoprotein (MSP): identification of homologous sequences in EST databases and analysis of their evolution during speciation.

Authors:  C Lazure; M Villemure; D Gauthier; R J Naudé; M Mbikay
Journal:  Protein Sci       Date:  2001-11       Impact factor: 6.725

7.  The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor.

Authors:  H von der Kammer; C Jurincic-Winkler; R Horlbeck; K F Klippel; H U Pixberg; K H Scheit
Journal:  Urol Res       Date:  1993-05

8.  Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.

Authors:  Christopher A Haiman; Daniel O Stram; Andrew J Vickers; Lynne R Wilkens; Katharina Braun; Camilla Valtonen-André; Mari Peltola; Kim Pettersson; Kevin M Waters; Loic Le Marchand; Laurence N Kolonel; Brian E Henderson; Hans Lilja
Journal:  J Natl Cancer Inst       Date:  2012-12-03       Impact factor: 13.506

9.  Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.

Authors:  Xing Wang; James E Hayes; Xing Xu; Xiaoni Gao; Dipti Mehta; Hans G Lilja; Robert J Klein
Journal:  Gene       Date:  2020-10-26       Impact factor: 3.688

10.  Prostate Secretory Protein of 94 amino acids (PSP94) binds to prostatic acid phosphatase (PAP) in human seminal plasma.

Authors:  Jenifer H Anklesaria; Dhanashree D Jagtap; Bhakti R Pathak; Kaushiki M Kadam; Shaini Joseph; Smita D Mahale
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.